Antonin Rollet de Fougerolles

Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA.

Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.

Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA.

Chimeron Bio Corp. is a biotechnology company based in the USA that is focused on developing a pipeline of products in oncology, rare genetic disorders, and infectious diseases using its proprietary chaesar™ platform. The American company is researching self-amplifying RNA (sRNA) to develop novel RNA drugs and vaccines for various diseases. Chimeron Bio is combining a first-in-class platform and the science of synthetic genomics to develop a robust portfolio of self-amplifying RNA therapeutics. The company was founded by Jolly Mazumdar, and the CEO is Kevin J. Heyeck.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.